Novosom granted US and European patents for RNAi-delivering Smarticles

16-May-2008

Novosom AG announced that it has been granted patents for both the USA and Europe for its drug delivery technology Smarticles®. Smarticles® are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells.

The US patent is entitled "Amphoteric liposomes and their use" and the US patent number is US 7371404. At the same time, the European Patent Office granted patent number EP 1363601 with the same title.

Elias Papatheodorou, CEO of Novosom, said, "We are delighted to be granted these US and European patents for our world-class RNAi and siRNA drug delivery sytem Smarticles®. In addition to the patents already granted Novosom, this forms a part of the strong intellectual property position Novosom is building in the growing field of nucleic-acid drugs based on RNA interference."

In March, ProNAi, a collaboration partner of Novosom announced the successful completion of the IND for the drug candidate PNT2258 which uses the Smarticle® delivery technology for a novel class of oligonucleotide therapeutics against multiple cancer types.

Other news from the department research and development

Most read news

More news from our other portals

All autoclave manufacturers at a glance